• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Biomea Fusion Inc. (Amendment)

    2/12/24 12:58:07 PM ET
    $BMEA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BMEA alert in real time by email
    SC 13G/A 1 biomea123123.txt JHG OWNS <5% UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Amendment No.: 3* Name of Issuer: Biomea Fusion, Inc. Title of Class of Securities: Common Stock CUSIP Number: 09077A106 Date of Event Which Requires Filing of this Statement: 12/31/2023 Check the appropriate box to designate the rule pursuant to which this Schedule is filed. [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No.: 09077A106 1. NAME OF REPORTING PERSON S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON Janus Henderson Group plc EIN #00-0000000 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP a. ___ b. ___ 3. SEC USE ONLY 4. CITIZENSHIP OR PLACE OF ORGANIZATION Jersey, Channel Islands NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH: 5. SOLE VOTING POWER 0** 6. SHARED VOTING POWER 1,718,245** 7. SOLE DISPOSITIVE POWER 0** 8. SHARED DISPOSITIVE POWER 1,718,245** 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,718,245** 10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES Not applicable 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 4.8%** 12. TYPE OF REPORTING PERSON IA, HC ** See Item 4 of this filing Item 1. (a). Name of Issuer: Biomea Fusion, Inc. ("Biomea") (b). Address of Issuer's Principal Executive Offices: 900 Middlefield Road, 4th Floor Redwood City, CA 94063 Item 2. (a).-(c). Name, Principal Business Address, and Citizenship of Persons Filing: (1) Janus Henderson Group plc 201 Bishopsgate EC2M 3AE, United Kingdom Citizenship: Jersey, Channel Islands (d). Title of Class of Securities: Common Stock (e). CUSIP Number: 09077A106 Item 3. This statement is filed pursuant to Rule 13d-1(b) or 13d-2(b) and the person filing, Janus Henderson Group plc ("Janus Henderson") is a parent holding company/control person in accordance with Section 240.13d-1(b)(ii)(G). See Item 4 for additional information. Item 4. Ownership The information in items 1 and 5 through 11 on the cover page(s) on Schedule 13G is hereby incorporated by reference. Janus Henderson has a 100% ownership stake in Janus Henderson Investors U.S. LLC ("JHIUS"), Janus Henderson Investors UK Limited ("JHIUKL") and Janus Henderson Investors Australia Institutional Funds Management Limited ("JHIAIFML"), (each an "Asset Manager" and collectively as the "Asset Managers"). Due to the above ownership structure, holdings for the Asset Managers are aggregated for purposes of this filing. Each Asset Manager is an investment adviser registered or authorized in its relevant jurisdiction and each furnishing investment advice to various fund, individual and/or institutional clients (collectively referred to herein as "Managed Portfolios"). Item 5. Ownership of Five Percent or Less of a Class The Managed Portfolios, set forth in Item 4 above, have the right to receive all dividends from, and the proceeds from the sale of, the securities held in their respective accounts. This statement is being filed to report the fact that the reporting persons have ceased to be the beneficial owners of more than five percent of the class of securities. These shares were acquired in the ordinary course of business, and not with the purpose of changing or influencing control of the Issuer. Item 6. Ownership of More than Five Percent on Behalf of Another Person Not applicable. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company JHIUS, JHIUKL and JHIAIFML are indirect subsidiaries of Janus Henderson and are registered investment advisers furnishing investment advice to Managed Portfolios. Item 8. Identification and Classification of Members of the Group Not applicable. Item 9. Notice of Dissolution of Group Not applicable. Item 10. Certification By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired in the ordinary course of business and were not acquired for the purpose of and do not have the effect of changing or influencing the control of the issuer of such securities and were not acquired in connection with or as a participant in any transaction having such purposes or effect. SIGNATURES After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. JANUS HENDERSON GROUP PLC By /s/ Kristin Mariani Kristin Mariani, Head of North America Compliance, CCO Date 2/12/2024 Name/Title Attorney-In-Fact The original statement shall be signed by each person on whose behalf the statement is filed or his or her authorized representative. If the statement is signed on behalf of a person by his or her authorized representative other than an executive officer or general partner of the filing person, evidence of the representative's authority to sign on behalf of such person shall be filed with the statement (see Exhibit A), provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his or her signature. EXHIBIT A POWER OF ATTORNEY The undersigned, Janus Henderson Group plc ("the Company"), does hereby make, constitute and appoint each of Kristin Mariani and Caroline Barotti acting severally, as its true and lawful attorneys in-fact, for the purpose of, from time to time, executing in its name and on its behalf, whether the Company individually or as representative of others, any and all documents, certificates, instruments, statements, other filings and amendments to the foregoing (collectively, "documents") determined by such person to be necessary or appropriate to comply with ownership or control-person reporting requirements imposed by any United States or non-United States governmental or regulatory authority, including, without limitation, Forms 13D, 13F, 13G and 13H and any amendments to any of the foregoing as may be required to be filed with the Securities and Exchange Commission, and delivering, furnishing or filing any such documents with the appropriate governmental, regulatory authority or other person, and giving and granting to each such attorney-in-fact power and authority to act in the premises as fully and to all intents and purposes as the Company might or could do if personally present by one of its authorized signatories, hereby ratifying and confirming all that said attorney-in-fact shall lawfully do or cause to be done by virtue hereof. Any such determination by an attorney-in-fact named herein shall be conclusively evidenced by such person's execution, delivery, furnishing or filing of the applicable document. This power of attorney shall be valid from the date hereof and shall remain in full force and effect until either revoked in writing by the Company, or, in respect of any attorney-in-fact named herein, until such person ceases to be an employee of the Company or one of its affiliates. IN WITNESS WHEREOF, the undersigned has caused this power of attorney to be executed as of this 9th day of December, 2022. Janus Henderson Group plc By: /s/ Michelle Rosenberg Name: Michelle Rosenberg Title: General Counsel and Company Secretary
    Get the next $BMEA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BMEA

    DatePrice TargetRatingAnalyst
    10/9/2024$128.00Buy
    Edward Jones
    9/27/2024$18.00Neutral → Buy
    Rodman & Renshaw
    9/27/2024$54.00Hold → Buy
    Truist
    8/29/2024$25.00Overweight
    CapitalOne
    6/11/2024Buy → Hold
    Truist
    6/7/2024$30.00 → $5.00Overweight → Equal Weight
    Barclays
    4/2/2024$51.00 → $14.00Overweight → Neutral
    JP Morgan
    2/6/2024$55.00Buy
    Truist
    More analyst ratings

    $BMEA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Biomea Fusion Inc.

      SC 13G/A - Biomea Fusion, Inc. (0001840439) (Subject)

      11/12/24 12:31:45 PM ET
      $BMEA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Biomea Fusion Inc.

      SC 13G/A - Biomea Fusion, Inc. (0001840439) (Subject)

      7/10/24 6:39:58 AM ET
      $BMEA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Biomea Fusion Inc.

      SC 13G - Biomea Fusion, Inc. (0001840439) (Subject)

      4/10/24 9:45:50 AM ET
      $BMEA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BMEA
    Leadership Updates

    Live Leadership Updates

    See more
    • Biomea Fusion Reports First Quarter 2025 Financial Results and Corporate Highlights

      Company Announces Strategic Realignment to Focus on Core Programs and Extend Cash Runway Icovamenib progressing toward the next phase of clinical development in insulin deficient type 2 diabetes patients and patients that are currently uncontrolled on a GLP-1 based therapyBiomea's next generation oral GLP-1 receptor agonist (BMF-650) filing for IND All other clinical and preclinical activities are either being partnered or closed REDWOOD CITY, Calif., May 05, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. ("Biomea" or "Biomea Fusion" or "the Company") (NASDAQ:BMEA), a clinical-stage diabetes and obesity company, today reported its financial results for the first quarter ended March 31, 202

      5/5/25 4:05:00 PM ET
      $BMEA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Biomea Fusion Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights

      Mick Hitchcock, Ph.D., appointed Interim Chief Executive OfficerBiomea preparing icovamenib for late-stage clinical developmentMultiple milestones anticipated in 2025 including:FDA meeting anticipated in first half 2025 to discuss icovamenib late-stage development in severe insulin deficient patientsCOVALENT-111 (T2D) 52-week data anticipated in second half 2025COVALENT-112 (T1D) open label data anticipated in second half 2025BMF-650 IND application submission planned in second half 2025 REDWOOD CITY, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. ("Biomea" or "Biomea Fusion" or "the Company") (NASDAQ:BMEA), a clinical-stage diabetes and obesity medicines company, reported

      3/31/25 4:10:00 PM ET
      $BMEA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Biomea Fusion Announces Leadership Transition

      Board member Mick Hitchcock, named interim CEO replacing Thomas Butler. COO and President Ramses Erdtmann continuing at Biomea in current role. REDWOOD CITY, Calif., March 25, 2025 (GLOBE NEWSWIRE) --  Biomea Fusion, Inc. ("Biomea," or the "Company") (NASDAQ:BMEA), a clinical-stage diabetes and obesity medicines company, announced today an executive leadership change to help ensure the company realizes its full potential developing a novel therapy for diabetes. Specifically, Mick Hitchcock, a current board member since 2021, will succeed Thomas Butler as interim Chief Executive Officer. The change is effective immediately. "As a long-time member of Biomea's Board, I've had the privilege

      3/25/25 7:00:00 PM ET
      $BMEA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BMEA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Interim CEO Hitchcock Michael J.M.

      4 - Biomea Fusion, Inc. (0001840439) (Issuer)

      3/28/25 4:15:03 PM ET
      $BMEA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Financial Officer Valle Franco was granted 495 shares, increasing direct ownership by 1% to 42,995 units (SEC Form 4)

      4 - Biomea Fusion, Inc. (0001840439) (Issuer)

      12/2/24 4:30:08 PM ET
      $BMEA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Hitchcock Michael J.M. bought $100,600 worth of shares (10,000 units at $10.06), increasing direct ownership by 200% to 15,000 units (SEC Form 4)

      4 - Biomea Fusion, Inc. (0001840439) (Issuer)

      10/1/24 4:30:12 PM ET
      $BMEA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BMEA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Edward Jones initiated coverage on Biomea Fusion with a new price target

      Edward Jones initiated coverage of Biomea Fusion with a rating of Buy and set a new price target of $128.00

      10/9/24 8:20:08 AM ET
      $BMEA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Biomea Fusion upgraded by Rodman & Renshaw with a new price target

      Rodman & Renshaw upgraded Biomea Fusion from Neutral to Buy and set a new price target of $18.00

      9/27/24 7:30:48 AM ET
      $BMEA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Biomea Fusion upgraded by Truist with a new price target

      Truist upgraded Biomea Fusion from Hold to Buy and set a new price target of $54.00

      9/27/24 7:29:46 AM ET
      $BMEA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BMEA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Hitchcock Michael J.M. bought $100,600 worth of shares (10,000 units at $10.06), increasing direct ownership by 200% to 15,000 units (SEC Form 4)

      4 - Biomea Fusion, Inc. (0001840439) (Issuer)

      10/1/24 4:30:12 PM ET
      $BMEA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Financial Officer Valle Franco was granted 4,448 shares and bought $55,361 worth of shares (12,509 units at $4.43), increasing direct ownership by 66% to 42,500 units (SEC Form 4)

      4 - Biomea Fusion, Inc. (0001840439) (Issuer)

      6/12/24 4:30:07 PM ET
      $BMEA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BMEA
    Financials

    Live finance-specific insights

    See more
    • Biomea Fusion Announces Positive Topline Results from Ongoing Phase II COVALENT-111 Study in Patients with Type 2 Diabetes

      Icovamenib met the primary endpoint, displaying a meaningful statistically significant placebo-corrected mean reduction in HbA1c in the prespecified per protocol patient populationBest response achieved in target, beta-cell deficient patients on one or more antidiabetic agents at baseline, showing a placebo-adjusted mean reduction of 1.47% in HbA1c at Week 26 with statistical significance, after only 12 weeks of dosing icovamenib with 100 mgIcovamenib was well-tolerated, with no adverse-event related discontinuations, no hypoglycemic events and no serious adverse events REDWOOD CITY, Calif., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. ("Biomea" or "Biomea Fusion" or "the Company

      12/17/24 8:10:00 AM ET
      $BMEA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Biomea Fusion to Host Conference Call to Announce Topline Results from Phase II COVALENT-111 Study in Patients with Type 2 Diabetes (T2D)

      REDWOOD CITY, Calif., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. ("Biomea") (NASDAQ:BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing oral covalent small molecules to treat and improve the lives of patients with diabetes, obesity, and genetically defined cancers, today announced that it will host a conference call and webcast on Tuesday, December 17, 2024 at 8:00 am EST to present topline results from COVALENT-111, the company's Phase II trial of icovamenib in patients with type 2 diabetes. Conference Call and Webcast Details Webcast of Biomea's investor update on Tuesday, December 17, 2024, at 8:00 am EST will be available to reg

      12/16/24 6:15:01 PM ET
      $BMEA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Biomea Fusion Announces Preliminary Data from Ongoing COVALENT-103 Study of Investigational Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia

      Preliminary data supports BMF-500's potential as a transformative therapy for patients with FLT3 mutated relapsed or refractory (R/R) acute leukemiaBMF-500 showed a favorable safety and tolerability profile, with no dose-limiting toxicities observed across all dose levelsPharmacokinetic and pharmacodynamic data confirmed on-target FMS-like tyrosine kinase 3 (FLT3) inhibition, demonstrating dose-proportional activity and good compartmental penetrationPreliminary Phase I data for BMF-500 in R/R acute leukemia patients with FLT3 gene mutations having failed gilteritinib indicated clinical activity with evidence of responses, including a first complete response with incomplete hematologic recove

      12/9/24 4:01:00 PM ET
      $BMEA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BMEA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Biomea Fusion Reports First Quarter 2025 Financial Results and Corporate Highlights

      Company Announces Strategic Realignment to Focus on Core Programs and Extend Cash Runway Icovamenib progressing toward the next phase of clinical development in insulin deficient type 2 diabetes patients and patients that are currently uncontrolled on a GLP-1 based therapyBiomea's next generation oral GLP-1 receptor agonist (BMF-650) filing for IND All other clinical and preclinical activities are either being partnered or closed REDWOOD CITY, Calif., May 05, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. ("Biomea" or "Biomea Fusion" or "the Company") (NASDAQ:BMEA), a clinical-stage diabetes and obesity company, today reported its financial results for the first quarter ended March 31, 202

      5/5/25 4:05:00 PM ET
      $BMEA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

      REDWOOD CITY, Calif., April 01, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. ("Biomea" or the "Company") (NASDAQ:BMEA), a clinical-stage diabetes and obesity medicines company, today announced that on March 23, 2025, the compensation committee of Biomea's board of directors granted two new employees non-qualified stock options to purchase an aggregate of 30,000 shares of the Company's common stock. The shares underlying each employee's stock options will vest 1/16 on a quarterly basis over four years, in each case subject to each such employee's continued employment with the Company on such vesting dates. All of the above-described awards were made under Biomea's 2023 Inducement Equity Pla

      4/1/25 4:01:00 PM ET
      $BMEA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Biomea Fusion Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights

      Mick Hitchcock, Ph.D., appointed Interim Chief Executive OfficerBiomea preparing icovamenib for late-stage clinical developmentMultiple milestones anticipated in 2025 including:FDA meeting anticipated in first half 2025 to discuss icovamenib late-stage development in severe insulin deficient patientsCOVALENT-111 (T2D) 52-week data anticipated in second half 2025COVALENT-112 (T1D) open label data anticipated in second half 2025BMF-650 IND application submission planned in second half 2025 REDWOOD CITY, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. ("Biomea" or "Biomea Fusion" or "the Company") (NASDAQ:BMEA), a clinical-stage diabetes and obesity medicines company, reported

      3/31/25 4:10:00 PM ET
      $BMEA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BMEA
    SEC Filings

    See more
    • SEC Form 10-Q filed by Biomea Fusion Inc.

      10-Q - Biomea Fusion, Inc. (0001840439) (Filer)

      5/5/25 4:10:21 PM ET
      $BMEA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Biomea Fusion Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Biomea Fusion, Inc. (0001840439) (Filer)

      5/5/25 4:05:08 PM ET
      $BMEA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by Biomea Fusion Inc.

      DEF 14A - Biomea Fusion, Inc. (0001840439) (Filer)

      4/28/25 4:05:34 PM ET
      $BMEA
      Biotechnology: Pharmaceutical Preparations
      Health Care